This Government Contract opportunity from Department Of Veterans Affairs was posted on July 31, 2026. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

Q301--Lab Testing Services - clonoSEQ Measurable Residual Disease Test Pittsburgh VA Medical Center - Pittsburgh, PA

Closed

36C24426Q0855Federal

Submission Closed08/10/2026, 12:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 621511

New

International

Accredited DNA Testing ProviderThis subcontract for the City and County of Swansea requires an accredited DNA testing provider to support safeguarding and social care projects. The selected provider will be responsible for the end-to-end testing process, including identity verification, the collection of buccal swab samples, and strict chain of custody management. Technical requirements include performing DNA profiling and comparison within accredited sequencing laboratories to ensure the highest standards of accuracy. Beyond laboratory analysis, the provider must deliver formal verified reports and provide expert witness testimony for court hearings. This opportunity was posted on October 20, 2026, with a response deadline of November 16, 2026. The services fall under NAICS code 621511, focusing on specialized medical diagnostic services to support legal and social care outcomes.

City & County of Swansea

POSTED

DEADLINE

Accredited Drug and Alcohol Testing ProviderThis subcontract agreement establishes an Accredited Drug and Alcohol Testing Provider to support prime contractors on statutory projects for the City and County of Swansea. The selected provider is responsible for the end-to-end testing process, including field or clinic-based sample collection, the management of a secure chain of custody to ensure legal admissibility, and comprehensive laboratory analysis. To maintain these standards, the provider must utilize accredited laboratory facilities and secure transport containers. Beyond technical testing, the provider is required to deliver professional test reports and offer expert interpretation of results. This scope of work extends to legal support, requiring the provider to furnish expert witness testimony during legal proceedings. Interested parties must respond by November 16, 2026, in accordance with the solicitation posted on October 20, 2026.

City & County of Swansea

POSTED

DEADLINE

Framework Agreement for DNA, Drug and Alcohol Testing Services

Solicitation # CCS/26/257

The City and County of Swansea is establishing a Framework Agreement under solicitation CCS/26/257 for accredited testing services to support statutory functions, including social care, safeguarding, and legal proceedings. The framework is divided into two lots: Lot 1 for Drug and Alcohol Testing Services and Lot 2 for DNA Testing Services, with each lot having an estimated value of 350,000 GBP excluding VAT. The scope of work includes identity verification for DNA testing and expert witness support where required. The agreement is scheduled to run from January 11, 2027, to January 10, 2032, with an option to extend for an additional 24 months through January 10, 2034. A maximum of six suppliers may be appointed to the framework, and the council may award contracts through either direct award or mini-competition. This procurement is designated as a light touch regime and is open to small and medium-sized enterprises as well as voluntary, community, and social enterprises. Interested parties must submit their tenders electronically via the eTenderWales portal by November 16, 2026, at 12:00pm. Submissions are accepted in both English and Welsh, and bidders may apply for one or both available lots.

City & County of Swansea

POSTED

DEADLINE

STAT Clinical Laboratory Testing & AnalysisThis subcontract for STAT Clinical Laboratory Testing and Analysis supports prime contractors on Department of Veterans Affairs healthcare system projects. The selected provider will perform 24/7/365 analysis and monitoring of patient specimens, ensuring immediate notification of critical results and the delivery of final written reports within five working days. To qualify, the provider must employ board-certified pathologists and maintain a NYS DOH Clinical Laboratory Permit and a CLIA license. Additionally, the facility must hold accreditation from either the College of American Pathologists or the Joint Commission. This opportunity is categorized under NAICS code 621511 and is managed by the Department of Veterans Affairs Network Contract Office 02.

242-NETWORK Contract Office 02 (36C242)

POSTED

DEADLINE

Q301--FY27 (BASE+4) STAT Laboratory Testing - Syracuse (VA-27-00010334)

Solicitation # 36C24227Q0069

The Department of Veterans Affairs VISN 2 Network Contracting Office intends to award a firm fixed-price contract for STAT laboratory testing services at the Syracuse VA Medical Center. The proposed contract structure includes a base period followed by four option periods. The government intends to sole source this requirement to University Pathologists Laboratories under FAR 6.302-1(a)(2), though this special notice serves as market research to identify other capable providers, including various small business socioeconomic categories. The scope of work involves the 24/7, 365-day-a-year analysis, monitoring, and reporting of clinical and surgical specimens, utilizing advanced methods such as electron microscopy and molecular studies. Key operational requirements include picking up specimens within 30 minutes of a request and delivering final written reports within five working days. Critical results require immediate notification to authorized providers. To be eligible, the contractor must employ board-certified pathologists and accredited technologists and maintain mandatory certifications, including a NYS Department of Health Clinical Laboratory Permit, a CLIA license, and CAP or Joint Commission accreditation. This acquisition falls under NAICS code 621511. Interested parties must provide documentation of their technical expertise and socioeconomic status to the contracting officer within 10 calendar days of the notice publication.

242-NETWORK Contract Office 02 (36C242)

POSTED

DEADLINE

Specialized Cell Source & Biobank SupplyThis subcontract opportunity with the National Institutes of Health, under the Department of Health and Human Services, focuses on the supply and qualification of human cell sources and biological resources for prime contractors working on NIAID infectious disease projects. The selected provider will be responsible for sourcing, characterizing, and qualifying primary cells or human cell lines that represent diverse human variability, utilizing genomic characterization tools and cryogenic storage to ensure quality and stability. The scope of work includes performing essential qualification of cell sources as a project benchmark and delivering fully characterized tissue samples or cell lines. Interested parties should note that the response deadline is January 29, 2027, and the project falls under NAICS code 621511.

National Institutes Of Health

POSTED

DEADLINE

Forensic Toxicology Laboratory ServicesThis subcontract for Forensic Toxicology Laboratory Services supports Florida Department of Transportation drug testing projects by providing professional analysis of collected drug and alcohol specimens for prime contractors. The selected provider is responsible for analyzing specimens for controlled substances, processing split samples, and delivering all test results and reports to the Medical Review Officer. To qualify, the provider must operate a certified forensic toxicology laboratory that adheres to all USDOT and FMCSA standards. This opportunity falls under NAICS code 621511, with a response deadline set for November 4, 2026.

Florida Department of Transportation

POSTED

DEADLINE

Controlled Substances and Alcohol Use Testing

Solicitation # DOT-RFP-27-9020-JM

The Florida Department of Transportation is soliciting competitive proposals under solicitation number DOT-RFP-27-9020-JM for third-party controlled substances and alcohol use testing program management services. The selected vendor will be responsible for administering testing for CDL drivers and other department employees, including random selection and testing using scientifically valid methods, providing Substance Abuse Professional services for rehabilitation monitoring, and maintaining 24-hour emergency collection coordination. The scope of work requires strict adherence to federal regulations, including USDOT 49 CFR Part 40 and FMCSA 49 CFR Part 382, as well as the Florida Drug-Free Workplace Act. Deliverables include a secure, password-protected website for results and statistical reporting, with monthly itemized invoicing submitted through the MyFloridaMarketplace system. The procurement process requires a two-part submission consisting of a technical proposal and a price proposal. To be considered responsive, proposers must achieve a minimum average score of 70 points on the technical evaluation, which is weighted across a management plan, work plan, executive summary, and technical plan. The contract is planned for performance across multiple fiscal years from 2027 through 2031. Eligible bidders must be registered in MyFloridaMarketplace, authorized to do business in Florida, and compliant with scrutinized companies lists and non-discrimination statutes. Evaluation is based on the grand total of tests, fees, and services, and the department reserves the right to conduct on-site reviews of facilities and qualifications prior to contract execution.

Florida Department of Transportation

POSTED

DEADLINE

Referral Laboratory ServicesThis subcontract for Referral Laboratory Services supports prime contractors on Department of Veterans Affairs projects under Network Contracting Office 6. The scope of work involves performing referral laboratory testing and diagnostic services, utilizing electronic systems for the ordering and reporting of results. To ensure clinical quality and data security, the provider must maintain CLIA certification and CMS-deemed status through either the College of American Pathologists or The Joint Commission. Additionally, strict adherence to HIPAA regulations is required for the handling of all patient data. The contract is categorized under NAICS code 621511.

246-NETWORK Contracting Office 6 (36C246)

POSTED

DEADLINE

Karius Liquid Biopsy / Cell-Free DNA Testing ServicesThis subcontract involves the provision of specialized diagnostic testing services for prime contractors supporting the Department of Veterans Affairs Caribbean Healthcare System in San Juan. The scope of work focuses on the processing of clinical specimens using Karius-specific liquid biopsy protocols and the analysis of cell-free DNA to identify infectious agents. To qualify, the service provider must utilize the Karius testing platform technology and maintain current CLIA certification. The contract emphasizes strict adherence to HIPAA compliance to ensure the secure electronic transmission of sensitive patient data. Deliverables include the provision of secure electronic test results and detailed diagnostic reports. This opportunity is categorized under NAICS code 621511 and is managed by the Department of Veterans Affairs Network Contract Office 8.

248-NETWORK Contract Office 8 (36C248)

POSTED

DEADLINE

Q501--STAT CLINICAL LAB TESTING AND AUTOPSIES

Solicitation # 36C24627Q0076

The Department of Veterans Affairs, Network Contracting Office 6, is conducting market research through a Sources Sought Notice to identify qualified businesses capable of providing comprehensive referral laboratory testing, specimen transportation, and autopsy services. The primary service area includes the Hunter Holmes McGuire VA Medical Center and associated Central Virginia VA Health Care System locations. The scope of work encompasses clinical and anatomic pathology requirements, including analytical testing, the processing and maintenance of specimen integrity, STAT testing, and medical autopsy services involving gross and microscopic examinations. The contractor will also be responsible for providing secure specimen transportation, consultative services for test selection and interpretation, and electronic access to patient results. This opportunity is open to various small business concerns, including SDVOSBs, VOSBs, 8(a), HUBZone, WOSB, and EDWOSB entities, under NAICS code 621511 with a size standard of 45.5 million dollars. Providers must maintain strict compliance with HIPAA regulations and hold essential certifications, such as CLIA and CMS-deemed status through organizations like the College of American Pathologists or The Joint Commission. Interested parties must submit a capability statement not exceeding five pages to Gordon Burns by October 27, 2026, at 1:00 p.m. ET. This notice is for acquisition planning purposes only and does not constitute a formal solicitation or a guarantee of a future contract award.

246-NETWORK Contracting Office 6 (36C246)

POSTED

DEADLINE

Solicitation # 36C24827Q0069

The Department of Veterans Affairs, through Network Contracting Office 8 for the VA Caribbean Healthcare System in San Juan, Puerto Rico, has issued a Sources Sought Notice under solicitation number 36C24827Q0069. This notice is for market research purposes to identify qualified businesses capable of providing the Karius Next-Generation Sequencing (NGS) Infectious Disease Test, a cell-free DNA diagnostic tool used to identify infectious microorganisms in the blood. The government is specifically looking for providers under NAICS code 621511 for Medical Laboratories, which has a size standard of 41.5 million dollars. The required scope of work includes providing all necessary transport supplies such as lab test request forms, shipping containers with required preservatives, and tracking air bills to ensure specimen integrity. The contractor must also provide a communication method for VACHS laboratories to inquire about pending tests and deliver secure electronic test results and reports within established timeframes. Interested parties must be registered in the System for Award Management and submit a qualifications letter including company details, UEI, socio-economic category, a technical capability statement, and evidence of past performance. Responses must be emailed to Contract Specialist Eunice Bones by 1:00 PM EST on October 23, 2026, with the subject line RFI# 36C24827Q0069 - Karius Test.

248-NETWORK Contract Office 8 (36C248)

POSTED

2 days ago

DEADLINE

in 2 days

AI Contract Overview

The Department of Veterans Affairs’ Network Contracting Office 4 intends to award a sole source contract to Adaptive Biotechnologies Corporation for the provision of clonoSEQ Measurable Residual Disease (MRD) testing services at the Pittsburgh VA Medical Center. This action is justified under FAR 6.103-1 because Adaptive Biotechnologies is the exclusive provider of the clonoSEQ assay, a proprietary, FDA-cleared, and CLIA-validated molecular test used to detect MRD in patients with multiple myeloma, B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and other lymphoid malignancies. The contract will use simplified acquisition procedures, be firm fixed price, and span a five-year period with an annual quantity of 100 tests. The solicitation number is 36C24426Q0855, and the NAICS code is 621511 with a size standard of $41.5 million. Any interested party may submit a capability statement prior to the response deadline of August 10, 2026, at 8:00 AM Eastern Standard Time, but the Government retains full discretion to proceed without competition based on the unique nature of the technology and the absence of viable alternatives. Responses must include the company name, SAM UEI number, address, point of contact details, business size, and evidence demonstrating the ability to perform the service, including relevant experience, contract numbers, dollar amounts, performance periods, and customer contacts. All submissions must be emailed to Mickeya Linzie at mickeya.linzie@va.gov and must clearly state whether the respondent is the direct provider or an authorized reseller. No submissions will be accepted after the deadline, and all information provided becomes the property of the Government.

General Info

Sole source contract to Adaptive Biotechnologies for clonoSEQ MRD testing at Pittsburgh VA, five years, 100 tests annually.

Agency

Department Of Veterans Affairs → 244-NETWORK Contract Office 4 (36C244)

NAICS

621511 - Medical Laboratories

Place of Performance

Set-Aside

NONE

Documents

36C24426Q0855 Sole Source Notice for clonoSEQ MRD Testing at Pittsburgh VA

sources-sought

Low

AI Contract Breakdown

Uniform Contract Format

Timeline

PhaseClosed

PostedJul 31

special-notice

Response DeadlineAug 10

Deadline has passed

Submission Closed

08/10/2026, 12:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Veterans Affairs → 244-NETWORK Contract Office 4 (36C244)

Contacts1 person available

OfficePITTSBURGH, PA, 15215, USA

Organization / AgencyDepartment Of Veterans Affairs → 244-NETWORK Contract Office 4 (36C244)

Office AddressPITTSBURGH, PA, 15215, USA

Contacts

Mickeya LinzieContracting Officer

contact@example.gov

+1 (555) 000-0000

Full Description

NOTICE OF INTENT TO AWARD SOLE SOURCE: The Department of Veterans Affairs (VA) Regional Procurement Office East (RPOE), Network Contracting Office 4 (NCO 4) intends to award a sole source contract pursuant to RFO FAR 6.103-1 to Adaptive Biotechnologies Corporation located at 1165 Eastlake AVE E, Seattle, Washington 98109. Simplified acquisition procedures will be used, and the resulting contract will be firm priced for a five-year period.
The Pittsburgh VA Medical Center requires a contractor to provide clonoSEQ Measurable Residual Disease (MRD) Testing. This service shall be provided for the Department of Veterans Affairs, Pittsburgh VA Medical Center, located at University Drive, Pittsburgh, PA 15240. The clonoSEQ assay is provided exclusively by Adaptive Biotechnologies and is a proprietary, FDA-cleared, patented molecular test developed and performed exclusively by Adaptive Biotechnologies for MRD detection in bone marrow from patients with multiple myeloma and B-cell acute lymphoblastic leukemia (B-ALL), and in blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). It is also a CLIA-validated laboratory developed (LDT) test for diffuse large B-cell lymphoma (DLBCL) and other lymphoid malignancies. Adaptive Biotechnologies is the sole source provider of clonoSEQ MRD testing within the United States. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet the VA facility s needs.
Line Item Description Annual Quantity 1 ClonoSEQ MRD Testing 100
THIS NOTICE IS NOT A REQUEST FOR COMPETITIVE QUOTES; however, any responsible firm that believes it can meet the requirement shall give written notification and capability statements prior to the response due date and time. Vendors shall indicate if they are the direct supplier or service provider of the items and/or authorized reseller/distributor. Supporting evidence shall be furnished in sufficient detail to demonstrate the ability to perform the requirement and shall include relevant experience along with the applicable contract number(s), total contract dollar amount, contract period of performance, details of the relevant supply and/or services, and customer point of contact with corresponding telephone number and email address.
Responses shall include following information: 1. Company Name 2. SAM UEI Number 3. Company s Address 4. Point of Contact Information (title, phone number and email address) 5. Business Size
Responses received will be evaluated; however, a determination by the Government not to compete the proposed procurement based on responses to this notice is solely within the discretion of the Government. Information provided will not be returned. Responses are due by Monday, 8/10/2026 at 8:00 AM Eastern Standard Time. No submissions will be accepted after this date and time. Responses shall be submitted via email to Mrs. Mickeya Linzie at mickeya.linzie@va.gov.
The NAICS code for this acquisition is 621511 (Medical Laboratories) and the size standard is $41.5 million.